RBCC Target Amarantus Wins MANF Patent Challenge in Europe

  RBCC Target Amarantus Wins MANF Patent Challenge in Europe

Business Wire

NOKOMIS, Fla. -- December 05, 2012

Rainbow Coral Corp. (OTCBB: RBCC) joint venture target Amarantus Bioscience,
Inc. (OTCQB: AMBS) recently won a major victory when its patent for MANF, the
company’s proprietary anti-apoptosis therapeutic protein, was challenged in

The Opposition Division of the European Patent Office upheld Amarantus’
European Patent relating to the neurotrophic factor following opposition by
rival Hermo Pharma OY of Finland.

The Opposition Division held that Hermo Phrama’s arguments did not prejudice
the maintenance of the patent as originally granted, with broad claims
covering MANF and its derivatives. The Opponent had not contested the validity
of the patent on the basis of novelty or inventive step, but had objected to
the broad scope of the claims. After due consideration, the Opposition
Division rejected the Hermo Pharma’s arguments and upheld the claims without

“This is a highly significant decision for Amarantus, after an extended period
of uncertainty,” said Marc Wilkinson PhD, European Patent Attorney of UK firm
Avidity IP, representing Amarantus. “The Opposition Division’s decision
validates broad protection for MANF and derivatives across major European

The decision was significant for RBCC, as well. The company’s biotech
subsidiary, Rainbow Biosciences, is close to finalizing a joint venture with
Amarantus to develop and market new therapies and treatments for neurological
diseases including Parkinson’s and Traumatic Brain Injury (TBI) around the
world. By upholding the patent, the European Patent Office has cleared the way
for potentially lucrative promotion and distribution of MANF on that

Amarantus recently received millions in new funding to continue their research
and development work. The joint venture’s first priority will be the speedy
commercialization of Amarantus’ NuroPro, a sophisticated test developed to
more accurately and easily diagnose Parkinson’s disease.

For more information on Rainbow BioSciences’ neurological treatment
initiatives, please visitwww.rainbowbiosciences.com/investors.html.

RainbowBioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ:AMGN),Cell Therapeutics, Inc. (NASDAQ:CTIC) and Abbott Laboratories

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit our website at [www.RainbowBioSciences.com]. For investment
information and performance data on the company, please

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information included
herein for events occurring after the date hereof.


Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
Press spacebar to pause and continue. Press esc to stop.